Libratus

NVAX- Dark horse in the vaccine race

看多
NASDAQ:NVAX   Novavax, Inc.
No one can predict the result of NVAX's phase 3 trial. However, I don't count out any potential winners in the vaccine race even though now it seems very likely that NVAX won't be the first one to distribute vaccines at massive scale.

That being said, as long as the result of phase 3 trial isn't a complete failure, I think the crowd frenzy will keep pushing NVAX's price up.

To be on the safe side, I would market buy 33% of my overall position and limit buy the remaining in the demand zone.

Just my opinion. Not the investment advice.


免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。